Kewaunee Scientific Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4928541048
USD
40.14
-0.37 (-0.91%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

6.63 k

Shareholding (Oct 2025)

FII

3.14%

Held by 16 FIIs

DII

80.96%

Held by 16 DIIs

Promoter

0.00%

How big is Kewaunee Scientific Corp.?

22-Jun-2025

As of Jun 18, Kewaunee Scientific Corp. has a market capitalization of 105.10 million and reported net sales of 220.02 million and a net profit of 17.82 million over the latest four quarters.

As of Jun 18, Kewaunee Scientific Corp. has a market capitalization of 105.10 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 220.02 million for the latest four quarters and a net profit of 17.82 million during the same period.<BR><BR>As of Apr 24, the shareholder's funds were 54.76 million, and total assets amounted to 134.77 million.

View full answer

What does Kewaunee Scientific Corp. do?

22-Jun-2025

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory and healthcare furniture products, operating in the Pharmaceuticals & Biotechnology industry. As of January 2025, it reported net sales of $67 million and a market cap of $105.10 million.

Overview:<BR>Kewaunee Scientific Corporation is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 67 Million (Quarterly Results - Jan 2025) <BR>Most recent Net Profit: 1 Million (Quarterly Results - Jan 2025) <BR>Market cap: USD 105.10 Million (Micro Cap) <BR><BR>Key Metrics:<BR>P/E: 6.00 <BR>Debt Equity: 0.51 <BR>Return on Equity: 29.30% <BR>Price to Book: 1.73 <BR><BR>Contact Details:<BR>Address: 2700 W Front St, STATESVILLE NC: 28677 <BR>Tel: 1 704 8737202 <BR>Website: http://www.kewaunee.com/

View full answer

Should I buy, sell or hold Kewaunee Scientific Corp.?

22-Jun-2025

Who are in the management team of Kewaunee Scientific Corp.?

22-Jun-2025

As of March 2022, the management team of Kewaunee Scientific Corp. includes Mr. David Rhind (Independent Chairman), Mr. Thomas Hull (President and CEO), and four Independent Directors: Mr. Keith Gehl, Ms. Margaret Pyle, Mr. John Russell, and Mr. Donald Shaw. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Kewaunee Scientific Corp. includes the following individuals:<BR><BR>- Mr. David Rhind, Independent Chairman of the Board<BR>- Mr. Thomas Hull, President, Chief Executive Officer, Director<BR>- Mr. Keith Gehl, Independent Director<BR>- Ms. Margaret Pyle, Independent Director<BR>- Mr. John Russell, Independent Director<BR>- Mr. Donald Shaw, Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

View full answer

Is Kewaunee Scientific Corp. overvalued or undervalued?

20-Sep-2025

As of June 30, 2025, Kewaunee Scientific Corp. is considered undervalued with a P/E ratio of 6 and strong long-term performance, despite a year-to-date return of -26.30%, contrasting with the S&P 500's 12.22% return.

As of 30 June 2025, Kewaunee Scientific Corp. has moved from expensive to attractive, indicating a shift in its valuation perspective. The company is currently considered undervalued, supported by a P/E ratio of 6, a Price to Book Value of 1.85, and an EV to EBITDA ratio of 7.61. In comparison, Pro-Dex, Inc. has a higher P/E of 14.77 and an EV to EBITDA of 10.46, while Lucid Diagnostics, Inc. shows a negative P/E, highlighting Kewaunee's relative attractiveness in its sector.<BR><BR>Despite a challenging year-to-date return of -26.30% compared to the S&P 500's 12.22%, Kewaunee has shown strong long-term performance with a 3-year return of 146.49% versus the S&P 500's 70.41%. This suggests that while recent performance has been weak, the company's long-term growth potential remains compelling.

View full answer

Is Kewaunee Scientific Corp. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Kewaunee Scientific Corp. shows a mildly bearish trend despite a recent 5.85% weekly outperformance compared to the S&P 500, with year-to-date returns at -26.30% versus the S&P's 12.22%.

As of 11 September 2025, the technical trend for Kewaunee Scientific Corp. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by weekly and monthly MACD indicators both showing a mildly bearish signal, along with the Bollinger Bands indicating a mildly bearish trend on the weekly chart. The moving averages present a mildly bullish signal on the daily timeframe, but this is overshadowed by the overall bearish indicators. Additionally, the Dow Theory shows a mildly bearish stance on the monthly timeframe. <BR><BR>In terms of performance, Kewaunee has outperformed the S&P 500 over the past week with a return of 5.85% compared to 1.05%, but it has underperformed over the longer periods, with a year-to-date return of -26.30% versus the S&P 500's 12.22%.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Company has a low Debt to Equity ratio (avg) at times

 
2

Low Debt Company with Strong Long Term Fundamental Strength

 
3

The company has declared negative results in Jan'2025 after 9 consecutive positive quarters

4

With ROE of 29.30%, it has a attractive valuation with a 1.85 Price to Book Value

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 112 Million (Micro Cap)

stock-summary
P/E

6.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.38

stock-summary
Return on Equity

17.22%

stock-summary
Price to Book

1.60

Revenue and Profits:
Net Sales:
70 Million
(Quarterly Results - Oct 2025)
Net Profit:
3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.6%
0%
-2.6%
6 Months
-27.52%
0%
-27.52%
1 Year
-37.54%
0%
-37.54%
2 Years
34.07%
0%
34.07%
3 Years
148.54%
0%
148.54%
4 Years
176.64%
0%
176.64%
5 Years
219.59%
0%
219.59%

Kewaunee Scientific Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
10.26%
EBIT Growth (5y)
65.91%
EBIT to Interest (avg)
2.99
Debt to EBITDA (avg)
0.57
Net Debt to Equity (avg)
0.39
Sales to Capital Employed (avg)
3.20
Tax Ratio
21.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
47.54%
ROCE (avg)
18.08%
ROE (avg)
11.29%

Valuation key factors

Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
1.85
EV to EBIT
9.67
EV to EBITDA
7.61
EV to Capital Employed
1.56
EV to Sales
0.65
PEG Ratio
0.06
Dividend Yield
NA
ROCE (Latest)
16.14%
ROE (Latest)
29.30%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Oct 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 11 Schemes (15.9%)

Foreign Institutions

Held by 16 Foreign Institutions (3.14%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Oct'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Oct 2025 is -1.41% vs -7.78% in Jul 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Oct 2025 is -21.88% vs -34.69% in Jul 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Oct'25",
        "Jul'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "70.10",
          "val2": "71.10",
          "chgp": "-1.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "5.70",
          "val2": "6.40",
          "chgp": "-10.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.10",
          "val2": "1.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "2.50",
          "val2": "3.20",
          "chgp": "-21.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "58.60%",
          "val2": "67.60%",
          "chgp": "-0.90%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is 18.01% vs -7.15% in Apr 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is -39.27% vs 1,264.29% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "240.50",
          "val2": "203.80",
          "chgp": "18.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "22.50",
          "val2": "21.40",
          "chgp": "5.14%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.20",
          "val2": "1.80",
          "chgp": "77.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "11.60",
          "val2": "19.10",
          "chgp": "-39.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "73.90%",
          "val2": "89.70%",
          "chgp": "-1.58%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Oct'25 - QoQstock-summary

Oct'25
Jul'25
Change(%)
Net Sales
70.10
71.10
-1.41%
Operating Profit (PBDIT) excl Other Income
5.70
6.40
-10.94%
Interest
1.10
1.10
Exceptional Items
0.00
0.00
Consolidate Net Profit
2.50
3.20
-21.88%
Operating Profit Margin (Excl OI)
58.60%
67.60%
-0.90%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Oct 2025 is -1.41% vs -7.78% in Jul 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Oct 2025 is -21.88% vs -34.69% in Jul 2025

Annual Results Snapshot (Consolidated) - Apr'25stock-summary

Apr'25
Apr'24
Change(%)
Net Sales
240.50
203.80
18.01%
Operating Profit (PBDIT) excl Other Income
22.50
21.40
5.14%
Interest
3.20
1.80
77.78%
Exceptional Items
0.00
0.00
Consolidate Net Profit
11.60
19.10
-39.27%
Operating Profit Margin (Excl OI)
73.90%
89.70%
-1.58%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Apr 2025 is 18.01% vs -7.15% in Apr 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Apr 2025 is -39.27% vs 1,264.29% in Apr 2024

stock-summaryCompany CV
About Kewaunee Scientific Corp. stock-summary
stock-summary
Kewaunee Scientific Corp.
Pharmaceuticals & Biotechnology
Kewaunee Scientific Corporation is engaged in the design, manufacture and installation of laboratory, healthcare and technical furniture products. The Company's products include steel, wood and laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. It operates through two segments: Domestic and International. The Domestic business segment designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment provides facility design, engineering, construction and project management from the planning stage through testing and commissioning of laboratories.
Company Coordinates stock-summary
Company Details
2700 W Front St , STATESVILLE NC : 28677
stock-summary
Tel: 1 704 8737202
stock-summary
Registrar Details